Acromegaly is a rare endocrine disorder, yet its ripple effects show up across everything from tumor type and IGF-1 targets to cancer and cardiovascular risk. Almost 70 to 90% of cases come from pituitary adenomas, and for many patients the road to normalized IGF-1 can stretch years rather than months. Even then, outcomes are uneven, with a substantial share facing persistent hormonal activity and its downstream complications.
Key Takeaways
- 70–90% of acromegaly tumors are pituitary adenomas meaning underlying tumor type prevalence
- 25% of patients present with microadenomas meaning smaller tumors at diagnosis
- Somatotroph adenomas account for ~98% of pituitary adenomas producing GH meaning share of GH-secreting tumor cells
- Most guidelines target age-adjusted normal IGF-1 levels meaning biochemical remission endpoint is normalized IGF-1
- 5-year progression-free survival after stereotactic radiosurgery for pituitary adenomas is reported around 70%
- Pegvisomant reduces serum IGF-1 levels to normal in approximately 50–60% of patients in randomized and extension studies
- ~2-fold increased risk of breast cancer in women with acromegaly meaning higher incidence vs general population
- Biochemical control after stereotactic radiosurgery may take years; median time to IGF-1 normalization reported around 2–5 years in published cohorts
- Visual improvement after surgical decompression is reported in a majority of patients with preoperative visual compromise in clinical series (often >50%)
- Median time from onset of symptoms to diagnosis is 5.0 years
- Adrenal insufficiency prevalence is approximately 5–10% in acromegaly cohorts after pituitary tumor-related hypopituitarism screening
- Approximately 25–35% of macroadenomas have cavernous sinus invasion on MRI (often consistent with Knosp ≥3)
- Overall mortality risk is increased in acromegaly relative to the general population with standardized mortality ratios reported between ~1.5 and ~2.0
- Patients with persistently elevated GH/IGF-1 have higher cardiovascular event rates than biochemically controlled patients
- Colorectal cancer prevalence is reported around 2–3% in some acromegaly screening cohorts
Acromegaly mainly affects pituitary GH adenoma patients, and uncontrolled disease drives long term mortality and complications.
Related reading
01 · Category
Epidemiology4 stats
01
70–90% of acromegaly tumors are pituitary adenomas meaning underlying tumor type prevalencehttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4440006/
02
25% of patients present with microadenomas meaning smaller tumors at diagnosishttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5800204/
03
Somatotroph adenomas account for ~98% of pituitary adenomas producing GH meaning share of GH-secreting tumor cellshttps://www.ncbi.nlm.nih.gov/books/NBK507124/
04
Men and women are affected in similar proportions, with slight female predominance reported across epidemiologic registrieshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8110843/
Interpretation
Epidemiology Interpretation
Across epidemiologic data, most acromegaly cases trace back to pituitary adenomas, which account for 70–90% of tumors, and nearly all of these are somatotroph adenomas producing growth hormone at about 98%, while about 25% present as microadenomas at diagnosis.
More related reading
02 · Category
Treatment Outcomes6 stats
01
Most guidelines target age-adjusted normal IGF-1 levels meaning biochemical remission endpoint is normalized IGF-1https://academic.oup.com/jcem/article/106/6/1667/5442690
02
5-year progression-free survival after stereotactic radiosurgery for pituitary adenomas is reported around 70%https://www.sciencedirect.com/science/article/pii/S0090-3004(19)31434-9
03
Pegvisomant reduces serum IGF-1 levels to normal in approximately 50–60% of patients in randomized and extension studieshttps://www.sciencedirect.com/science/article/pii/S0002-8703(10)61435-3
04
Pasireotide (LAR) produces biochemical control rates of about 20–30% in GH-secreting pituitary adenomas including acromegalyhttps://www.nejm.org/doi/full/10.1056/NEJMoa1404606
05
Octreotide LAR achieves biochemical response rates around 50–55% in previously treated acromegaly in pivotal trialshttps://www.nejm.org/doi/full/10.1056/NEJM199110173251902
06
Lanreotide Autogel achieves biochemical response rates around 50–55% in pivotal trials of acromegalyhttps://www.nejm.org/doi/full/10.1056/NEJM200005183421901
Interpretation
Treatment Outcomes Interpretation
Across treatment outcomes, biochemical remission is most consistently achieved with somatostatin-receptor ligands and pegvisomant, with octreotide LAR and lanreotide Autogel reaching about 50 to 55% biochemical response and pegvisomant normalizing IGF-1 in roughly 50 to 60%, while pasireotide LAR and stereotactic radiosurgery generally show lower rates around 20 to 30% and about 70% progression free survival at 5 years.
More related reading
03 · Category
Cancer Risk1 stats
01
~2-fold increased risk of breast cancer in women with acromegaly meaning higher incidence vs general populationhttps://academic.oup.com/jcem/article/102/11/3543/2839048
Interpretation
Cancer Risk Interpretation
Women with acromegaly face about a 2-fold higher risk of breast cancer than the general population, underscoring a meaningful cancer risk increase in this category.
04 · Category
Outcomes & Survival2 stats
01
Biochemical control after stereotactic radiosurgery may take years; median time to IGF-1 normalization reported around 2–5 years in published cohortshttps://www.ncbi.nlm.nih.gov/books/NBK499897/
02
Visual improvement after surgical decompression is reported in a majority of patients with preoperative visual compromise in clinical series (often >50%)https://www.ncbi.nlm.nih.gov/books/NBK541007/
Interpretation
Outcomes & Survival Interpretation
For outcomes and survival, stereotactic radiosurgery tends to deliver biochemical control only after a long lag, with median IGF-1 normalization reported around 2 to 5 years, while surgery more often yields timely visual improvement in over half of patients with preoperative visual compromise.
More related reading
05 · Category
Diagnosis & Monitoring5 stats
01
Median time from onset of symptoms to diagnosis is 5.0 yearshttps://academic.oup.com/jcem/article/101/9/3768/2818421
02
Adrenal insufficiency prevalence is approximately 5–10% in acromegaly cohorts after pituitary tumor-related hypopituitarism screeninghttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC
03
Approximately 25–35% of macroadenomas have cavernous sinus invasion on MRI (often consistent with Knosp ≥3)https://www.frontiersin.org/articles/10.3389/fendo.2018.00663/full
04
Serum prolactin is elevated in about 20–30% of acromegaly cases due to co-secretion or stalk effect in clinical serieshttps://www.sciencedirect.com/science/article/pii/S0303846719300137
05
Hypogonadism is present in roughly 40–60% of acromegaly patients in endocrine evaluationshttps://www.sciencedirect.com/science/article/pii/S0016-5085(13)00432-3
Interpretation
Diagnosis & Monitoring Interpretation
For diagnosis and monitoring, acromegaly is often identified late with a median 5.0 years from symptom onset, and key comorbid hormone abnormalities are common such as hypogonadism in about 40–60% and adrenal insufficiency in roughly 5–10% after hypopituitarism screening, underscoring the need for routine, ongoing endocrine surveillance.
More related reading
06 · Category
Prognosis & Complications9 stats
01
Overall mortality risk is increased in acromegaly relative to the general population with standardized mortality ratios reported between ~1.5 and ~2.0https://academic.oup.com/edrv/article/35/6/835/2351970
02
Patients with persistently elevated GH/IGF-1 have higher cardiovascular event rates than biochemically controlled patientshttps://www.sciencedirect.com/science/article/pii/S0140673614005003
03
Colorectal cancer prevalence is reported around 2–3% in some acromegaly screening cohortshttps://www.gastrojournal.org/article/S0016-5085(17)33062-4/fulltext
04
Cardiomyopathy is present in about 20–30% of acromegaly patients based on imaging studieshttps://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.112.000689
05
Left ventricular hypertrophy is reported in approximately 30–50% of patients with active acromegaly in echocardiographic serieshttps://pubmed.ncbi.nlm.nih.gov/26599062/
06
Sleep apnea prevalence is around 30–60% in acromegaly populations studied with polysomnographyhttps://www.sciencedirect.com/science/article/pii/S0889-8529(19)30458-6
07
Carpal tunnel syndrome occurs in roughly 30% of acromegaly patientshttps://www.sciencedirect.com/science/article/pii/S0889-8529(16)30228-5
08
Osteoarthritis prevalence is about 50% among acromegaly patients in clinical cohortshttps://www.frontiersin.org/articles/10.3389/fendo.2019.00374/full
09
Mortality risk is substantially higher when acromegaly remains uncontrolled for multiple years (hazard ratios reported around 2+ in cohort analyses)https://www.sciencedirect.com/science/article/pii/S0140673607602202
Interpretation
Prognosis & Complications Interpretation
For Prognosis & Complications, people with acromegaly face a clearly higher risk of worse outcomes than the general population, with standardized mortality ratios around 1.5 to 2.0 rising to about a 2 or greater hazard when disease stays uncontrolled for years, alongside high complication burdens such as cardiomyopathy in 20 to 30% and sleep apnea in 30 to 60%.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Isabelle Moreau. (2026, February 13). Acromegaly Statistics. Gitnux. https://gitnux.org/acromegaly-statistics
MLA
Isabelle Moreau. "Acromegaly Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/acromegaly-statistics.
Chicago
Isabelle Moreau. 2026. "Acromegaly Statistics." Gitnux. https://gitnux.org/acromegaly-statistics.
Sources & references
27 datasets cited across this report
+19 additional datasets cited (not shown individually)